Sanofi has tripled Beyfortus production and doubled manufacturing sites since its 2023 launch. Live on Wednesday June 18: 3 Summer "Power Patterns" Are About to Trigger (One With 90% Win Rate).

French drugmaker Sanofi SA (NASDAQ:SNY) on Monday said it is shipping Beyfortus (nirsevimab) starting in early Q3 to ensure broad availability well ahead of the 2025-2026 respiratory syncytial ...

Paris, June 9, 2025. Sanofi is shipping Beyfortus (nirsevimab) starting in early Q3 to ensure broad availability well ahead of the 2025-2026 respiratory syncytial virus (RSV) season, which typically ...

Sanofi said that the current Beyfortus supply for the upcoming RSV season “already matches the total doses distributed last year,” while production remains ongoing. The companies added that ...

Late-breaking data show infant respiratory syncytial virus (RSV) hospitalizations reduced by 69% in Spain following Beyfortus-only immunization targeted to all infants and 26.7% in the UK ...

Beyfortus has amassed real-world data in over 40 studies spanning four continents and more than 250,000 immunized infants - the largest body of public health impact data for infant RSV protection ...

Sanofi accelerates global shipping of Beyfortus to prepare healthcare providers months ahead of 2025-2026 RSV season Paris, June 9, 2025. Sanofi is shipping Beyfortus (nirsevimab) starting in ...

Paris, June 9, 2025. Sanofi is shipping Beyfortus (nirsevimab) starting in early Q3 to ensure broad availability well ahead of the 2025-2026 respiratory syncytial virus (RSV) season, which ...